eliquis apixaban logo eliquis apixaban logo eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

Dosing in NVAF

ELIQUIS (apixaban): Simple dosing for your patients with NVAF

desk-img mob-img

In the ARISTOTLE clinical trial, the majority of patients were on 5 mg BD (95.3%, n = 8,692/9,120).2*

Diagnosemethoden

It’s simple to switch your patients to ELIQUIS1

Dosing could differ for some patients with renal or hepatic impairment1


ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

BD = Twice Daily   
INR = International Normalised Ratio   
ISTH = International Society on Thrombosis and Haemostasis   
LMWH = Low Molecular Weight Heparin   
NVAF = Non-Valvular Atrial Fibrillation

* The ARISTOTLE clinical trial was a randomised, double-blind, double-dummy non-inferiority trial in 18,201 patients. Stroke / systemic embolism was the primary efficacy endpoint and major bleeding was the primary safety endpoint. The primary safety outcome was major bleeding, according to the criteria of the International Society on Thrombosis and Haemostasis (ISTH). Pre-specified hierarchical sequential testing was performed first on stroke / systemic embolism (primary efficacy endpoint) for non-inferiority, then for superiority, then on major bleeding and, finally, on death from any cause (secondary endpoint).2

References:

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.
  2. Granger CB et al. N Engl J Med 2011; 365: 981–992.